[{"id":"9fe9336c-203b-4e85-b83d-ab26cb858495","acronym":"OSIBOOST-2","url":"https://clinicaltrials.gov/study/NCT05748093","created_at":"2023-02-28T13:01:31.374Z","updated_at":"2024-07-02T16:35:06.690Z","phase":"Phase 4","brief_title":"Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat","source_id_and_acronym":"NCT05748093 - OSIBOOST-2","lead_sponsor":"Maastricht University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-01"},{"id":"ed788d65-0132-4f88-b51e-b0cbc192fc90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638763","created_at":"2022-12-06T15:57:59.939Z","updated_at":"2024-07-02T16:35:59.603Z","phase":"Phase 2","brief_title":"Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT05638763","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-12-06"},{"id":"6c975a09-ad7a-4753-bf03-1fb9ba24377a","acronym":"Posa-Pk","url":"https://clinicaltrials.gov/study/NCT03796533","created_at":"2023-06-15T19:08:12.630Z","updated_at":"2024-07-02T16:36:16.640Z","phase":"","brief_title":"Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity","source_id_and_acronym":"NCT03796533 - Posa-Pk","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" UGT1A4","pipe":"","alterations":" ","tags":["UGT1A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Noxafil (posaconazole)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 04/10/2023","primary_completion_date":" 04/10/2023","study_txt":" Completion: 04/10/2023","study_completion_date":" 04/10/2023","last_update_posted":"2022-02-24"},{"id":"73ea380b-7de2-400a-b9ef-31fcae769d41","acronym":"","url":"https://clinicaltrials.gov/study/NCT04725942","created_at":"2023-06-15T19:08:12.849Z","updated_at":"2024-07-02T16:36:35.479Z","phase":"","brief_title":"Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients","source_id_and_acronym":"NCT04725942","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" UGT1A4","pipe":"","alterations":" ","tags":["UGT1A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Noxafil (posaconazole)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-01-27"}]